PATENT CLAIM ANALYSIS

Application Number: 15978854
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "259300"]

Abstract:
The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.

Claim (Index 4):
The composition according to  claim 3 , wherein the antioxidant is in a range of 0.05-0.5% by total weight.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 93.0
- Lexical Diversity: 1.5814
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15537833', '14692070', '15537857', '14002313', '15328381']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7595955483675315
- 35 USC 102 Novelty (BERT): 0.5014835199698152
- Combined Prediction Score: 0.73378434552776
- Mean Citation Score: 184.920676
- Max Citation Score: 199.073
- Similarity Product: 124.19625694292785

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test